Navigation Links
Boosting Pharma Sales Force Effectiveness through Streamlined Internal Communications
Date:12/12/2007

CHAPEL HILL, N.C., Dec. 12 /PRNewswire/ -- The success of a pharmaceutical sales force is built on effective communication. Yet ineffective internal communication between sales reps and regional corporate sources are eating into reps' time on the job, according to a new study by benchmarking leader Best Practices, LLC.

Pharma sales reps spend an average of 13.7 hours a week managing internal communication and, of that, 4.4 hours (or 32 percent) are perceived as unnecessary, according to the study. Most of those 4.4 hours is made up of email and cell phone communications and a vast majority of the communications comes from regional and local sources, according to the study. Sales reps estimate they receive more than 150 email and voicemail communications a week from regional sources.

Pharmaceutical companies could increase sales staff productivity by more than 10 percent by eliminating unnecessary internal communications to the field, according to the study. To learn more about this report, Pharma Sales Force Effectiveness: Increasing Productivity Through Streamlined Internal Communication, please download a complimentary report excerpt and study overview at http://www3.best-in-class.com/rr890.htm

The research is based on interviews and benchmarking surveys from 10 leading pharmaceutical and biotech companies, including Pfizer, Eli Lilly, Genentech, Johnson & Johnson and Merck. Executives and managers who oversee sales operations can use this study to improve the productivity of their field sales force.

The research findings from this study highlight significant costs of unnecessary communication across a direct sales force as well as the best practices that sales communications functions, district managers, sales reps and IT managers can use to help prevent unnecessary internal communication.

Some of the key topics covered in the report include:

-- Total time spent on internal communication

-- Percentage of unnecessary time spent

-- Costs of unnecessary communication

-- Most effective communication methods

To learn more about this report, including key findings and sample best practices, download a complimentary excerpt at: http://www3.best-in- class.com/rr890.htm .

For questions or additional information on Best Practices, LLC's other products and services, please call Cameron Tew at 919-767-9246 or email ctew@best-in-class.com. Also, visit our Web site at: http://www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information, call 919-403-0251 or visit http://www3.best-in-class.com/.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Schools Getting Better at Boosting Kids Health
2. Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, ... $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro ... facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital ...
(Date:1/19/2017)... ... 19, 2017 , ... Workrite Ergonomics announced this week the ... privacy panel system was designed to deliver the ideal blend of acoustic and ... provide the visual privacy required to maintain concentration levels and increase productivity. The ...
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a family ... Virginia region, is inaugurating a charity event to honor Chad Phillip Dermyer, a local ... last year, Chad Phillip Dermyer and his fellow officers were conducting routine stops of ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the ... Medicine Associates of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, ... Williams have each been chosen by their peers for the 2017 list based ...
(Date:1/19/2017)... ... , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, announced today ... past 20 years SFI has been recognized as the world’s leader in Intelligent Sales ... the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, Stress Pal, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
(Date:1/19/2017)... -- Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, ...   Major research investment to work ...   The Milner Therapeutics Institute today announces ... partner to the Milner Therapeutics Consortium. Pfizer has agreed ... of materials between industry and academia and allocation of ...
(Date:1/19/2017)... 19, 2017 While various ... about reducing the FDA,s regulatory strictness as a ... medical drug industry, many of the leading biotech ... trials and development of advanced drug treatments and ... recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: